EXOC3

Across TCGA pan-cancer cohorts, EXOC3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EXOC3 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EXOC3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EXOC3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where EXOC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.942	0.767	<.001	65	view →
CCRCC	DFS	Tertile	II,III,IV	0.904	0.105	.008	21	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
LUAD	OS	Tertile	II,III,IV	0.300	0.764	.011	6	view →
LSCC	DFS	Tertile	All	0.496	1.000	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EXOC3–HNSC (OS)

Open the HNSC breakdown →